CR11307A - Vacunas - Google Patents

Vacunas

Info

Publication number
CR11307A
CR11307A CR11307A CR11307A CR11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A
Authority
CR
Costa Rica
Prior art keywords
malaria
vaccines
preeritrocyte
circumesporozoite
medicament
Prior art date
Application number
CR11307A
Other languages
English (en)
Inventor
William Ripley Ballou
Joseph D Cohen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39870250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CR11307A publication Critical patent/CR11307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere al uso de un antigeno derivado de la proteina circumesporozoito (CS) de Plasmodium falciparum que se expresa en la etapa preeritrocita de la infeccion por malaria combinado con un adyuvante farmaceuticamente aceptable, en la fabricacion de un medicamento para vacunar bebes contra la malaria.
CR11307A 2007-08-13 2010-03-10 Vacunas CR11307A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95544507P 2007-08-13 2007-08-13
US95733807P 2007-08-22 2007-08-22
US98280107P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
CR11307A true CR11307A (es) 2010-05-24

Family

ID=39870250

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11307A CR11307A (es) 2007-08-13 2010-03-10 Vacunas

Country Status (21)

Country Link
US (1) US9066899B2 (es)
EP (1) EP2190470B1 (es)
JP (1) JP5508266B2 (es)
KR (1) KR20100068390A (es)
AP (1) AP2010005166A0 (es)
AR (1) AR067905A1 (es)
AU (1) AU2008288508B2 (es)
BR (1) BRPI0815199A2 (es)
CA (1) CA2695477A1 (es)
CL (1) CL2008002361A1 (es)
CR (1) CR11307A (es)
DO (1) DOP2010000056A (es)
ES (1) ES2658347T3 (es)
MA (1) MA31693B1 (es)
MX (1) MX2010001752A (es)
NZ (1) NZ583150A (es)
TR (1) TR201802221T4 (es)
TW (1) TW200924791A (es)
UY (1) UY31285A1 (es)
WO (1) WO2009021931A1 (es)
ZA (1) ZA201001029B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
KR101616572B1 (ko) * 2009-05-05 2016-05-11 카딜라 핼쓰캐어 리미티드 홍역-말라리아 조합 백신
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
CA2769996C (en) * 2009-11-05 2018-06-12 The United States Of America As Represented By The Secretary Of The Na Plasmodium falciparum sporozoite and liver stage antigens
EP2385107B1 (en) * 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
KR20180096814A (ko) 2010-09-27 2018-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
CN102268093B (zh) * 2011-06-27 2013-06-26 广东药学院 一种肝靶向肽与人干扰素a2b融合蛋白及其制备方法和应用
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0071705B1 (en) 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9002512D0 (en) 1990-02-05 1990-04-04 3I Res Expl Ltd Polypeptides and dna encoding same
GB9012580D0 (en) 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5198535A (en) 1991-01-10 1993-03-30 The United States Of America As Represented By The Secretary Of The Navy Protective malaria sporozoite surface protein immunogen and gene
CA2123612C (en) 1991-11-16 2002-06-25 Michel De Wilde Hybrid protein between cs from plasmodium and h bsag
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998043690A1 (en) 1997-03-29 1998-10-08 Ji Hoon Park Continuous injecting apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO2002077195A2 (en) 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
EP2277533B1 (en) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria
US7550275B2 (en) 2002-11-12 2009-06-23 The United States Of America As Represented By The Secretary Of The Navy Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1754717A1 (en) * 2005-08-19 2007-02-21 Université de Lausanne Antigenic peptides and their use
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
EP2945649B1 (en) * 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition and uses thereof

Also Published As

Publication number Publication date
EP2190470B1 (en) 2017-12-13
UY31285A1 (es) 2009-03-31
CA2695477A1 (en) 2009-02-19
MA31693B1 (fr) 2010-09-01
ES2658347T3 (es) 2018-03-09
AU2008288508B2 (en) 2014-05-01
TW200924791A (en) 2009-06-16
WO2009021931A1 (en) 2009-02-19
US20110212159A1 (en) 2011-09-01
EP2190470A1 (en) 2010-06-02
BRPI0815199A2 (pt) 2015-03-31
DOP2010000056A (es) 2010-07-31
NZ583150A (en) 2012-05-25
US9066899B2 (en) 2015-06-30
AU2008288508A1 (en) 2009-02-19
CL2008002361A1 (es) 2009-08-07
JP5508266B2 (ja) 2014-05-28
TR201802221T4 (tr) 2018-03-21
AR067905A1 (es) 2009-10-28
KR20100068390A (ko) 2010-06-23
MX2010001752A (es) 2010-03-10
CN101820901A (zh) 2010-09-01
AP2010005166A0 (en) 2010-02-28
ZA201001029B (en) 2011-04-28
JP2010535836A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
UY31285A1 (es) Vacunas
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
UA93508C2 (en) Anti-malaria vaccine
CR10555A (es) Vacunas para malaria
CY1111553T1 (el) Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
CL2014002415A1 (es) Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11).
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
NO20071523L (no) Vaksiner
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
WO2008054535A3 (en) Novel influenza m2 vaccines
BR112012016048A2 (pt) "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
EA200701595A1 (ru) Устойчивые к спиртам лекарственные формы
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
UY31574A1 (es) Vacunas contra la malaria
NZ580603A (en) Intradermal influenza vaccine
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2010064208A3 (en) Msp2 antigenic peptides and their use
WO2010023452A3 (en) Nematode vaccine
ITRM20040041A1 (it) Vaccino per la cura della rosolia.
HU0402690D0 (en) Hiv virus antigen deprived of its virulence for manufacturing vaccine